The company reported $46.8 million, compared with $47.6 million over the same period last year. Net revenues were also down $1.7 million in the third quarter of 2012, driven by the company’s biologics process.
International sales reached $15.9 million, $1 million more than the same period last year. As part of a January 2012 settlement, the company agreed to pay $18 million to Cross Medical for a license agreement dispute, with $1 million paid during the third quarter.
The company recently launched a new spinous process fixation system, BridgePoint, and a new synthetic bone growth biologic, Alphatec NEXoss.
More Articles on Orthopedic Devices:
Globus Medical 3Q Worldwide Sales Reach $94.8M, Up 12.5%
X-spine Announces FDA Approval for 2 Spine Systems
Zimmer Pulls Metal-on-Metal Hip Device From Australia
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.